Can Opdivo (nivolumab) be combined with Yervoy (ipilimumab)?
Yes. Opdivo and Yervoy are commonly used together as a combination immunotherapy regimen in several cancers. Both medicines are checkpoint inhibitors with different targets: Opdivo blocks PD-1 and Yervoy blocks CTLA-4, and using them together can improve anti-tumor immune activity.
What cancers are typically treated with Opdivo + Yervoy?
Opdivo plus Yervoy is used in multiple settings across oncology, including advanced melanoma and certain lung cancer and kidney cancer indications, depending on the specific regimen and guideline-based selection.
How is the combination given, and is it different from single-agent Opdivo or Yervoy?
The combination is administered in a coordinated schedule, with patients receiving both drugs during the same treatment course rather than sequentially. Compared with single-agent therapy, combination treatment generally has higher immune-related side-effect risk, so clinicians monitor closely and may start steroids or pause treatment if immune toxicities occur.
What side effects should patients expect with Opdivo + Yervoy?
Immune-related adverse events are a key concern with both drugs and are more likely with combination therapy than with one agent alone. These can include inflammation affecting skin, colon/diarrhea, liver, lungs, hormone-producing glands, and other organs. Patients are usually instructed to report new or worsening symptoms promptly so treatment can be adjusted early.
Are there patent or market implications if you’re asking for Opdivo + Yervoy availability?
If your interest is partly about access, cost, or payer coverage, DrugPatentWatch.com can help track patent and exclusivity information for specific products and combinations. You can search for Opdivo and Yervoy on the site for the latest status: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/